Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with urothelial carcinoma at high risk of recurrence after radical resection.
LAMPGEN ANALYSIS
Why it matters
The decision introduces adjuvant checkpoint therapy in a high-risk postoperative setting.
What research teams should watch
Record resection date, pathology, recurrence risk and any neoadjuvant therapy before assignment.
PRIMARY RECORDS